Bioasis Technologies Inc. V.BTI

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

TSXV:BTI - Post by User

Bioasis Technologies Inc. > Consequences of a "no" vote: from IR

<< Previous

Bullboard Posts

Next >>

Comment by OttawaPeteron Jan 19, 2023 8:38pm

88 Views

Post# 35234621

RE:RE:RE:RE:RE:Consequences of a "no" vote: from IR

G1945V wrote:
G1945V wrote:
zwerp2000 wrote: So i am confused. If xB3 is really worth so much, how come BTI could not find a partner to help develop it and save them? Surely if there was any value to xB3, they could have found someone to partner with, no? Doesn't make sense to have such a valuable asset and have pretty much no one interested in using it after all of these years

Well, thank goodness Midatech Pharma PLC seems to have found some value in xB3!

G1945V

This could very well end up a YES vote from the BTI shareholders and a NO from Midatech Pharma PLC shareholders which would put BTI on the lurch. I wonder if this concern is in the minds of BTI management.

Midatech dropped by more than half of its December 12, 2022 share balance price when it was $1.65 US.

JMO
G1945V